EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy

Annals of Nuclear Medicine

Volumn 26, Issue 6, 2012, Pages 485-491

  Kurosaka, Shinji ^a   Satoh, Takefumi ^a   Chow, Edward ^b   Asano, Yuji ^a   Tabata, Ken Ichi ^a   Kimura, Masaki ^a   Tsumura, Hideyasu ^a   Matsumoto, Kazumasa ^a   Ishiyama, Hiromichi ^a   Inoue, Yusuke ^a   Hayakawa, Kazushige ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Bone metastases; Prostate cancer; Quality of life; Strontium 89

Indexed keywords

STRONTIUM 89;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; EORTC QLQ BM22 QUESTIONNAIRE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QLQ C30 QUESTIONNAIRE; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RADIOISOTOPE THERAPY; SINGLE DRUG DOSE; SOCIAL BEHAVIOR;

ALKALINE PHOSPHATASE; BONE NEOPLASMS; HUMANS; MALE; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; STRONTIUM RADIOISOTOPES;

EID: 84864720517     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0598-z     Document Type: Article

References (17)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Henkin RE, Del Rowe JD, Grigsby PW, Hartford AC, Jadvar H, Macklis RM, et al. ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical Sources. Clin Nucl Med. 2011;36(8):e72-80.
3. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43(1):79-86. (Pubitemid 34101193)
4. Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, Mason MD, Quilty PM, et al. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin Oncol. 1993;20(3 Suppl 2):32-3. (Pubitemid 23170170)
5. Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, et al. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer. 2009;45(7): 1146-52.
6. Chow E, Bottomley A. Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):461-5.
7. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76. (Pubitemid 23073154)
8. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17(6):1654-63. (Pubitemid 29269233)
9. Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006;24(18):2828-35. (Pubitemid 46630582)
10. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
11. Satoh T, Kobayashi K, Hori T, Iida S, Sato A, Ishiguro H, et al. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases - The Japanese version of the EORTC QLQBM22. Gan To Kagaku Ryoho. 2010;37(8):1507-12.
12. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574-81. (Pubitemid 28175783)
13. Chow E, Nguyen J, Zhang L, Tseng LM, Hou MF, Fairchild A, et al. International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer. 2012;118(5):1457-65.
14. Kuroda I. Effective use of strontium-89 in osseous metastases. Ann Nucl Med. 2011 (in press).
15. Yoshimura M, Saito K, Park J, Akata S, Koizumi K, Tokuue K, et al. Tumoricidal effect of strontium-89. Clin Nucl Med. 2011; 36(4):296-9.
16. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010;8(5):341-51.
17. Gunawardana DH, Lichtenstein M, Better N, Rosenthal M. Results: of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med. 2004;29(2):81-5. (Pubitemid 38240734)